This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.

The aims of this report were:

- To determine the role of fluorine-18 deoxyglucose (FDG)-positron emission tomography (PET) imaging in cancer management by evaluating the clinical and cost effectiveness in terms of impact on patient morbidity and mortality.

- To consider the best configuration of PET facilities and cyclotrons to serve Scotland, if PET was found to be clinically and cost effective.

A PET imaging facility including a cyclotron, dedicated to clinical use and specific health services research, should be set up in Scotland and linked to an existing specialist cancer centre. All patients who require re-staging of Hodgkin's disease should receive FDG-PET imaging in order to select those for surveillance or radical radiotherapy. PET research should be undertaken in other cancers, such as lung cancer (NSCLC and single pulmonary nodule), malignant melanoma and recurrent head and neck cancer, to inform economic modelling and patient outcome.